CytoMed Rejects False Claims About Research Programs
CytoMed Therapeutics issued a statement to address recent statements containing "inaccurate and misleading" claims regarding the Company's research programs, clinical progress, and operations.The company said, " CytoMed categorically rejects such claims which have no basis. Certain statements circulating publicly mis-characterize the Company's scientific focus, development status, and regulatory standing. Please refer to recent announcements by the Company on our progress. CytoMed's research is focused on CAR gammadelta T cell therapies and iPSC-derived gammadelta NKT cell therapies, based on established immunological science. The Company's lead CAR gammadelta T cell program has received regulatory approval to proceed with a first-in-human clinical trial, which is currently ongoing at National University Hospital, Singapore. This clinical activity is conducted in accordance with applicable regulatory and ethical requirements. Other programs, including iPSC-derived gammadelta NKT cell candidates, remain in preclinical development. CytoMed does not claim that any of its therapeutic candidates are approved for commercial use or clinically validated beyond their current stage of development. Assertions regarding CytoMed's regulatory status, manufacturing capabilities, governance, or financial transparency that contradict the above facts are inaccurate or taken out of context and designed to affect the Company's share price. The Company operates in compliance with applicable regulations and follows development practices appropriate for its stage. CytoMed remains committed to advancing its pipeline responsibly and to communicating accurate, timely information through official Company disclosures. The Company reserves the right to take appropriate action to address the dissemination of false or misleading information that may adversely affect its reputation or stakeholders."
Discover Tomorrow's Bullish Stocks Today
Analyst Views on GDTC
About GDTC
About the author
CytoMed Addresses False Claims, Reaffirms Research Progress
- Research Progress Statement: CytoMed is conducting its first CAR γδ T cell clinical trial at National University Hospital in Singapore, having received regulatory approval, marking a significant advancement in the company's cancer immunotherapy efforts, which is expected to drive further development of its product pipeline.
- Technological Focus: The company is focused on developing CAR γδ T cell and iPSC-derived γδ NKT cell therapies to address treatment needs for both blood and solid tumors, showcasing its innovative potential in the biopharmaceutical sector.
- Rebuttal of False Claims: CytoMed strongly rejects inaccurate statements regarding its research status and regulatory standing, emphasizing its commitment to compliance and transparency to protect shareholder interests and the company's reputation.
- Future Outlook: Despite external challenges, CytoMed remains dedicated to advancing its research pipeline and communicating accurate information through official channels, ensuring investor confidence in the company's future development.
CytoMed Enters MOU with UMMC for First-in-Human Cancer Trial
- Trial Collaboration Initiated: CytoMed has signed a Memorandum of Understanding with Universiti Malaya Medical Centre to conduct a multi-site first-in-human Phase I clinical trial, aimed at evaluating the safety and efficacy of its patented γδ T cell therapy for no-option cancer patients, marking a strategic expansion into the Southeast Asian market.
- Technological Advantage: By utilizing donor-derived γδ T cells, CytoMed's therapy circumvents the high costs and logistical complexities associated with autologous treatments, making cancer immunotherapy more accessible and potentially providing a cost-effective option for Malaysian patients.
- Clinical Research Backing: Collaborative research with MD Anderson Cancer Center has demonstrated the potential of γδ T cells in treating acute myeloid leukemia, further solidifying the scientific foundation for CytoMed's clinical trials and driving innovation in cancer treatment.
- Broad Market Potential: This partnership with UMMC not only underscores CytoMed's commitment to emerging markets but also facilitates business growth in Southeast Asia, addressing the increasing demand for cancer therapies and enhancing the company's competitiveness in the global biopharmaceutical industry.
